Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Accumulated Expenses (2016 - 2025)

Arrowhead Pharmaceuticals' Other Accumulated Expenses history spans 13 years, with the latest figure at $10.7 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 2326.14% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $10.7 million, up 2326.14%, while the annual FY2025 figure was $10.8 million, 2402.55% up from the prior year.
  • Other Accumulated Expenses reached $10.7 million in Q4 2025 per ARWR's latest filing, down from $10.8 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $10.8 million in Q3 2025 to a low of $17000.0 in Q1 2021.
  • Average Other Accumulated Expenses over 4 years is $2.9 million, with a median of $448000.0 recorded in 2025.
  • The largest YoY upside for Other Accumulated Expenses was 2402.55% in 2025 against a maximum downside of 21.82% in 2025.
  • A 4-year view of Other Accumulated Expenses shows it stood at $17000.0 in 2021, then surged by 2611.76% to $461000.0 in 2023, then fell by 4.56% to $440000.0 in 2024, then soared by 2326.14% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Other Accumulated Expenses are $10.7 million (Q4 2025), $10.8 million (Q3 2025), and $7.4 million (Q2 2025).